Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

This is the kind of catalyst that matters only if it lowers adoption friction, not because it creates demand on its own. For HROW, the economic value is in shortening the sales cycle with retina specialists and clinics that are already economically sensitive to workflow, reimbursement, and perceived clinical hassle. If IHEEZO and BYOOVIZ become more “default” choices in high-volume practices, the benefit is recurring and margin-accretive, but that showing usually appears in prescriptions and mix over the next 1-2 quarters, not in the conference day print.

Competitive spillovers are more interesting than the press release suggests. A credible biosimilar narrative in ranibizumab pressure-tests the economics of the whole anti-VEGF channel: incumbents may defend with rebates, which can reduce net pricing across adjacent products even if unit growth holds. That can help HROW on share but hurt gross-to-net realization if the company leans too hard on contracting to win placement. The second-order winner is any distributor or practice management channel that can bundle a lower-friction anesthetic plus retina therapy; the loser is the branded reference-product franchise that relies on physician inertia.

The key risk is that conference evidence does not convert into real-world switching. If next quarter shows no sequential lift in TRx/NRx, or if gross margin compresses from discounting, the market should treat this as noise. The contrarian view is that investors often overpay for “more evidence” when the real bottleneck is payer policy and stocking behavior, which can lag for months. In other words, this is a watchable but not automatically investable catalyst unless the company can show measurable uptake by the next reporting cycle.